Search

Your search keyword '"Achyut Guleri"' showing total 2 results
Start Over Author "Achyut Guleri" Journal the journal of antimicrobial chemotherapy
2 results on '"Achyut Guleri"'

1. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE)

Author

Philip Howard, John D. Perry, Richard P. Steeds, Bernard Prendergast, Achyut Guleri, Richard Watkin, Michael J. Spry, Muzahir H. Tayebjee, Gavin Barlow, Jonathan Sandoe, John C. Chambers, Ewan Olson, and Michael D. Gammage

Subjects
Pharmacology, Microbiology (medical), medicine.medical_specialty, Prosthesis-Related Infections, Joint working, business.industry, Cardiac Resynchronization Therapy Devices, Disease Management, Guideline, Audit, medicine.disease, Defibrillators, Implantable, Infectious Diseases, medicine.anatomical_structure, Infective endocarditis, Antimicrobial chemotherapy, Medicine, Humans, Pharmacology (medical), Professional association, Heart valve, business, Intensive care medicine
Abstract

Infections related to implantable cardiac electronic devices (ICEDs), including pacemakers, implantable cardiac defibrillators and cardiac resynchronization therapy devices, are increasing in incidence in the USA and are likely to increase in the UK, because more devices are being implanted. These devices have both intravascular and extravascular components and infection can involve the generator, device leads and native cardiac structures or various combinations. ICED infections can be life-threatening, particularly when associated with endocardial infection, and all-cause mortality of up to 35% has been reported. Like infective endocarditis, ICED infections can be difficult to diagnose and manage. This guideline aims to (i) improve the quality of care provided to patients with ICEDs, (ii) provide an educational resource for all relevant healthcare professionals, (iii) encourage a multidisciplinary approach to ICED infection management, (iv) promote a standardized approach to the diagnosis, management, surveillance and prevention of ICED infection through pragmatic evidence-rated recommendations, and (v) advise on future research projects/audit. The guideline is intended to assist in the clinical care of patients with suspected or confirmed ICED infection in the UK, to inform local infection prevention and treatment policies and guidelines and to be used in the development of educational and training material by the relevant professional societies. The questions covered by the guideline are presented at the beginning of each section.

Published
2014

2. Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context

Author

J. M. Stockley, Achyut Guleri, Andrew Kirby, E. Youngs, M. Farrington, Ruth Blackburn, P. Coe, P. Godwin, Robert Hill, Derrick W. Crook, P. Mannion, N. Todd, Russell Hope, Ibrahim A. Hassan, S. Majumdar, D. Mlangeni, Angela Kearns, J. Cunniffe, S. Morris Jones, J. Gardner, K. Loudon, David M. Livermore, Andrew Tuck, Neville Q. Verlander, Robin Howe, Robert Tilley, R. E. Warren, Guy E. Thwaites, Alan P. Johnson, Bharti Patel, Matthew Scarborough, Theodore Gouliouris, C. Marodi, R. Spencer, Josh Price, Simon Cotterill, A. Johnson, V. Weston, M. Llewellyn, Susan Hopkins, M. Lee, Elizabeth Sheridan, and D. Matthew

Subjects
Microbiology (medical), Adult, Male, Methicillin-Resistant Staphylococcus aureus, medicine.medical_specialty, Adolescent, Context (language use), Bacteremia, Microbial Sensitivity Tests, Staphylococcal infections, medicine.disease_cause, Agar dilution, Minimum inhibitory concentration, Young Adult, Vancomycin, Internal medicine, medicine, Humans, Pharmacology (medical), Child, Aged, Pharmacology, Aged, 80 and over, business.industry, Infant, Newborn, Infant, biochemical phenomena, metabolism, and nutrition, Middle Aged, Staphylococcal Infections, bacterial infections and mycoses, medicine.disease, Prognosis, Methicillin-resistant Staphylococcus aureus, United Kingdom, Surgery, Anti-Bacterial Agents, Infectious Diseases, Treatment Outcome, Child, Preschool, Female, Rifampin, business, Rifampicin, medicine.drug
Abstract

UNLABELLED: Received 29 November 2012; returned 20 February 2013; revised 16 May 2013; accepted 18 May 2013 OBJECTIVES: Raised vancomycin MICs have been associated with poor outcomes for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in the USA and mainland Europe. We investigated if this also applies in the UK, where EMRSA-15 (clonal complex 22) dominates. METHODS: Isolates from UK patients receiving vancomycin therapy for MRSA bacteraemia in 2008-10 were collected, along with clinical details. Outcomes (i.e. patient survival or bacteraemia resolution) were reported 28 days after vancomycin therapy ended. The relationship between clinical outcome and MIC--as determined by CLSI and BSAC agar dilution methods--was assessed. RESULTS: Among 228 MRSA bacteraemias, 82% were caused by EMRSA-15; 65% of the patients were male and the median age was 70.5 years. MICs correlated between methods, but CLSI agar dilution testing gave a mode at 1 mg/L with only 12% of results either side, whereas the BSAC method gave a mode straddling 0.7-1 mg/L with

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results